The American Journal of Managed Care2d
FDA Expands Semaglutide Use for CV, Kidney Risks in T2D, CKD
The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...
Ozempic vs. Semaglutide: 10 Weight Loss Medications Compared for 2025
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
JD Supra3d
The GLP-1 Saga Continues: FDA Ends the Tirzepatide Shortage: Frequently Asked Questions
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
Becker's Hospital Review10h
FDA warns GLP-1 compounder over safety rules
The FDA issued a warning letter to ProRx, a compounding facility in Exton, Penn., after an inspection raised serious concerns regarding the safety and compliance of its drug products. The facility, ...
Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...
Daily Jang1d
US FDA takes major decision about Ozempic amid its growing popularity
U.S Food and Drug Administration shared major news for patients who use Ozempic for type-2 diabetes.As per CNN, the GLP-1 ...